Pharmacy No. 84. Delivery of medicines to your home and office.

Delivery on Sundays and holidays does not work!

Medicines

my basket

Apteka84.kz is an online pharmacy that offers its customers medicines, medicinal and decorative cosmetics, dietary supplements, vitamins, baby food, intimate products for adults, medical equipment and thousands of other medical and cosmetic products at low prices. All data presented on the Apteka84.kz website is for informational purposes only and is not a substitute for professional medical care. Apteka84.kz strongly recommends that you carefully read the instructions for use contained in each package of medicines and other products. If you currently have any symptoms of the disease, you should seek help from a doctor. You should always tell your doctor or pharmacist about all the medicines you take. If you feel you need further help, please consult your local pharmacist or contact our GP online or by telephone.

Tripotassium bismuth dicitrate tablet film 120 mg x56

BISMUTH TRIPOTASSIUM DICITRATE Bismuth tripotassium citrate

Compound

1 tablet contains the active substance: bismuth tripotassium citrate - 304.6 mg, in terms of bismuth oxide - 120.0 mg.

Pharmacotherapeutic group

Antiulcer, antiseptic, intestinal and astringent

ATX code

А02ВХ05

pharmachologic effect

Gastroprotective and antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. Thus, the drug forms a protective layer, which for a long period of time protects the affected areas of the mucous membrane from the influence of aggressive factors. By increasing the synthesis of prostaglandin E, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsipogen.

Indications for use

• functional dyspepsia not associated with organic diseases of the gastrointestinal tract, • chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori, • peptic ulcer of the stomach and duodenum in the acute phase, including those associated with Helicobacter pylori, • syndrome irritable bowel disease, occurring predominantly with symptoms of diarrhea.

Contraindications

• increased individual sensitivity to the components of the drug, • pregnancy, • breastfeeding, • taking medications containing bismuth, • chronic renal failure, • children under 4 years of age.

Method of administration and dosage

Inside. The duration of the course of treatment and the dose of the drug are determined by the attending physician individually for each patient, depending on the nature of the disease. For adults and children over 12 years of age, the drug is prescribed 1 tablet 4 times a day, 30 minutes before meals (breakfast, lunch, dinner) and at night, or 2 tablets 2 times a day 30 minutes before meals (breakfast, dinner). Children aged 8 to 12 years are prescribed 1 tablet 2 times a day, 30 minutes before meals (breakfast, dinner). Children aged 4 to 8 years are prescribed at a dose of 8 mg/kg/day, depending on the child’s body weight, 1-2 tablets per day are prescribed (respectively, in 1-2 doses per day). In this case, the daily dose should be as close as possible to the calculated dose (8 mg/kg/day). The tablets are taken 30 minutes before meals with a small amount of water. It is recommended to swallow the tablet whole, without chewing or crushing, with a sufficient amount of water. It is not recommended to take the tablets with milk. The duration of treatment is usually from 4 to 8 weeks. After finishing taking the drug, it is not recommended to take medications containing bismuth (for example, Vikalin, Vikair) for 2 months. For eradication of Helicobacter pylori, it is advisable to use bismuth tripotassium citrate in combination with antibacterial drugs with anti-Helicobacter activity.

Release form

Film-coated tablets 120 mg. 7, 10, 14, 28, 30 tablets in blister packs made of polyvinyl chloride film and printed varnished aluminum foil. 7, 10, 14, 20, 28, 30, 50, 56, 60, 100, 112, 160 or 240 tablets in polyethylene terephthalate jars for medicines or polypropylene for medicines, sealed with high-density polyethylene lids with first opening control or polypropylene lids with a “push-turn” system or low-density polyethylene lids with first-opening control.

Terms of release from pharmacies

Available without a prescription.

Bismuth tripotassium dicitrate

BISMUTH TRIPOTASSIUM DICITRATE Bismuth tripotassium citrate

Compound

1 tablet contains the active substance: bismuth tripotassium citrate - 304.6 mg, in terms of bismuth oxide - 120.0 mg.

Pharmacotherapeutic group

Antiulcer, antiseptic, intestinal and astringent

ATX code

А02ВХ05

pharmachologic effect

Indications for use

Contraindications

Method of administration and dosage

Release form

Terms of release from pharmacies

Available without a prescription.

Tripotassium bismuth dicitrate 120 mg 56 pcs. film-coated tablets

pharmachologic effect

A drug that has a protective effect on the mucous membrane of the stomach and duodenum. Antiulcer drug.

Composition and release form Bismuth tripotassium dicitrate 120 mg 56 pcs. film-coated tablets

Tablets - 1 tablet:

Active substances: bismuth tripotassium dicitrate - 304.6 mg, which corresponds to the content of bismuth oxide - 120 mg;
Excipients: corn starch - 71.1 mg, potassium polyacrylate - 23.6 mg, povidone K25 - 17.7 mg, macrogol 6000 - 6 mg, magnesium stearate - 2 mg;
Film shell composition: hypromellose - 5.5 mg; titanium dioxide - 3 mg; macrogol-4000 - 1.5 mg.

7, 8, 10, 14, 28, 30, 50, 56, 60, 100, 112, 160 or 240 pcs. — cardboard cell packaging or polyethylene terephthalate cans (1, 2, 3, 4, 5, 6, 7, 8, 10, 16) — cardboard packs.

Description of the dosage form

Tablets, film-coated, white or almost white, round, biconvex, odorless or with a weak characteristic odor; two layers are visible on the cross section: a core of white or white with a yellowish tint and a film shell.

Directions for use and doses

Adults and children over 4 years old - orally 2-4 times a day 30 minutes before meals. The dose depends on the patient's age.

The course of treatment is 4-8 weeks. You should not take medications containing bismuth for the next 8 weeks.

To eradicate Helicobacter pylori, it is advisable to use bismuth tripotassium dicitrate in combination with antibacterial drugs that have anti-Helicobacter activity.

Pharmacodynamics

Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are formed, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric (hydrochloric) acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.

Pharmacokinetics

Bismuth tripotassium dicitrate is practically not absorbed from the gastrointestinal tract. However, small amounts of bismuth may enter the systemic circulation. It is excreted mainly in feces. A small amount of bismuth entering the plasma is excreted by the kidneys.

Indications for use Bismuth tripotassium dicitrate 120 mg 56 pcs. film-coated tablets

Peptic ulcer of the stomach and duodenum in the acute phase (including those associated with Helicobacter pylori); chronic gastritis and gastroduodenitis in the acute phase (including those associated with Helicobacter pylori); irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea; functional dyspepsia not associated with organic gastrointestinal diseases.

Contraindications

Severe renal dysfunction, pregnancy, lactation, hypersensitivity to bismuth tripotassium dicitrate.

Application of Bismuth tripotassium dicitrate 120 mg 56 pcs. film-coated tablets during pregnancy and breastfeeding

Contraindicated for use during pregnancy and lactation (breastfeeding).

It is used in children over 4 years of age according to the dosage regimen.

special instructions

Should not be used for more than 8 weeks.

During treatment, it is not recommended to exceed the established daily doses for adults and children.

At the end of the course of treatment in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 μg/l, and intoxication is observed only at a concentration of more than 100 μg/l.

During use, stool may turn black due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.

Side effects of Bismuth tripotassium dicitrate 120 mg 56 pcs. film-coated tablets

From the digestive system: transient effects are possible - nausea, vomiting, increased bowel movements, constipation.

Dermatological reactions: skin rash, itching.

From the side of the central nervous system: with long-term use in high doses - encephalopathy associated with the accumulation of bismuth in the central nervous system.

Drug interactions

If you take other medicines at the same time, as well as food and liquids, in particular antacids, milk, fruit and fruit juices, the effectiveness of bismuth tripotassium dicitrate may change.

De-Bismuth caps. 120 mg in a container pack. №10x6

Name

De-bismuth

Description

Hard gelatin capsules are cylindrical in shape with white hemispherical ends.

Main active ingredient

Bismuth tripotassium dicitrate

Release form

10 capsules in a blister pack made of polyvinyl chloride film and aluminum foil. Three or six blister packs along with instructions for use in a cardboard pack.

Dosage

120 mg

pharmachologic effect

Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, and hepatic compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandins E, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.

Indications for use

- peptic ulcer of the stomach and duodenum. - gastritis, accompanied by complaints of dyspepsia, for which eradication of Helicobacter pylori is recommended.

Directions for use and doses

For adults and children over 12 years of age, the drug is prescribed 1 capsule 4 times a day 30 minutes before meals and at night, or 2 capsules 2 times a day 30 minutes before meals. Children from 6 to 12 years old are prescribed at a rate of 8 mg/kg/day. Depending on the child’s weight, 1-3 capsules per day are prescribed (respectively, in 1-3 doses per day). In this case, the daily dose should be as close as possible to the calculated dose (8 mg/kg/day). Capsules should be taken 30 minutes before meals and washed down with a small amount of water. The duration of treatment is 4-8 weeks. Over the next 8 weeks, you should not use medications containing bismuth. To eradicate Helicobacter pylori, it is advisable to use De-Bismuth in combination with other antibacterial agents that have anti-Helicobacter activity.

Use during pregnancy and lactation

The use of De-Bismuth during pregnancy and lactation is contraindicated.

Precautionary measures

The drug should not be used for more than 8 weeks, and it is also not recommended to exceed the established daily doses for adults and children during treatment. During treatment with De-Bismuth, you should not use other drugs containing bismuth, as the risk of side effects increases. At the end of a course of treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 mcg/l, and intoxication is observed only at concentrations above 100 mg/l. When using De-Bismuth, stool may turn dark due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue. Prolonged use of large doses of bismuth-containing compounds is not recommended, since in some cases it can lead to reversible encephalopathy. The risk of encephalopathy, however, is minimal, provided that De-Bismuth is used in recommended doses. Children The drug is not used in children under 6 years of age. Effect on the ability to drive vehicles and operate machinery There is no data on the effect of De-Bismuth on the ability to drive vehicles and operate machinery.

Interaction with other drugs

Within half an hour after taking De-Bismuth, it is not recommended to take other medications internally, as well as take food and liquids, in particular antacids, milk, fruits and fruit juices. This is due to the fact that when taken orally simultaneously, they can affect the effectiveness of De-Bismuth.

Contraindications

- hypersensitivity to any component of the drug - severe renal dysfunction - pregnancy and lactation - children under 6 years of age

Compound

1 capsule contains: active substances: bismuth oxide (in the form of bismuth potassium citrate) – 120.0 mg. excipients: magnesium stearate, colloidal anhydrous silicon dioxide, potato starch. composition of gelatin capsule No. 0: gelatin, purified water, titanium dioxide E-171.

Overdose

Symptoms: Acute massive overdose can lead to renal failure with a delayed onset of up to 10 days. Treatment: After a single dose of a very high dose, treatment should include gastric lavage, followed by activated charcoal and osmotic laxatives. This reduces the absorption of bismuth, so additional therapeutic measures are not required. Bismuth concentrations in the blood and urine should be determined in cases of acute and chronic intoxication to determine whether symptoms are related to increased bismuth exposure. Chelation therapy with dimercaptosuccinic acid (DMSA) or dimercaptopropanesulfonic acid (DMPS) is used if symptoms are known to be caused by acute or chronic bismuth overdose. In severe renal failure, hemodialysis should be performed after chelation therapy.

Side effect

From the digestive system Very common (≥ 1/10): - Blackening of the stool may occur due to the formation of bismuth sulfide, but it can be easily distinguished from melena. Rarely (≥ 1/1000,

Storage conditions

In a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children! Shelf life: 2 years Do not use after the expiration date indicated on the package.

Buy De-Bismuth caps. 120 mg in a container pack. No. 10x6 in the pharmacy

Price for De-Bismuth caps. 120 mg in a container pack. №10x6

Instructions for use for De-Bismuth caps. 120 mg in a container pack. №10x6